Sobi reports Phase 3 clinical data for gout treatment candidate pozdeutinurad
Sobi has released results from the REDUCE-2 study showing that pozdeutinurad significantly reduces serum urate levels over a 12-month period.
Swedish pharmaceutical company Sobi has announced detailed findings from its pivotal Phase 3 REDUCE-2 trial. The study evaluated the efficacy and safety of pozdeutinurad, an investigational once-daily URAT1 inhibitor designed to manage chronic gout.
Clinical data indicates that the drug achieved statistically significant reductions in serum urate levels throughout the 12-month study period. These results suggest a durable treatment effect, addressing a primary clinical challenge in patients with persistent hyperuricemia.
Sobi plans to utilize these study results to support upcoming regulatory submissions. The outcome of the REDUCE-2 trial marks a milestone in the company's efforts to expand its specialist pharmaceutical portfolio.